Patents by Inventor Siddharth SUKUMARAN

Siddharth SUKUMARAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSING FOR ANTI-TRYPTASE ANTIBODIES
    Publication number: 20220348687
    Abstract: The present invention features, inter alia, methods of treating a patient having asthma by administering an anti-tryptase antibody (e.g., anti-tryptase beta antibody) to the patient, anti-tryptase antibodies (e.g., anti-tryptase beta antibodies) for use in treating asthma, and uses of anti-tryptase antibodies (e.g., anti-tryptase beta antibodies), e.g., in the manufacture of medicaments for treating asthma.
    Type: Application
    Filed: September 18, 2020
    Publication date: November 3, 2022
    Inventors: Joseph Haw-Ling LIN, Ryan Patrick OWEN, Sharon Marie RYMUT, Siddharth SUKUMARAN
  • DOSING FOR PREVENTION OR TREATMENT OF GRAFT VERSUS HOST DISEASE (GVHD) WITH IL-22 Fc FUSION PROTEINS
    Publication number: 20220144910
    Abstract: The invention relates to methods, uses, and compositions (e.g., articles of manufacture and kits) for preventing or treating graft versus host disease (GVHD) (e.g., acute or chronic GVHD, including corticosteroid-refractory acute GVHD).
    Type: Application
    Filed: January 25, 2022
    Publication date: May 12, 2022
    Inventors: Matthew KALO, Timothy Then-Chioh LU, Melicent Clare PECK, Siddharth SUKUMARAN, Yehong WANG, Chin Yat WONG, Peter William DAY
  • DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS
    Publication number: 20210139552
    Abstract: The invention relates to methods, uses, and compositions (e.g., articles of manufacture and kits) for the treatment of diseases associated with IL-22 (e.g., inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC (e.g., moderate to severe UC)) and Crohn's disease (CD)) and graft versus host disease (GVHD) (e.g., acute or chronic GVHD)).
    Type: Application
    Filed: August 20, 2020
    Publication date: May 13, 2021
    Inventors: Matthew KALO, Timothy Then-Chioh LU, Siddharth SUKUMARAN, Yehong WANG, Peter William DAY
  • DOSING FOR PREVENTION OR TREATMENT OF GRAFT VERSUS HOST DISEASE (GVHD) WITH IL-22 Fc FUSION PROTEINS
    Publication number: 20210023176
    Abstract: The invention relates to methods, uses, and compositions (e.g., articles of manufacture and kits) for preventing or treating graft versus host disease (GVHD) (e.g., acute or chronic GVHD, including corticosteroid-refractory acute GVHD).
    Type: Application
    Filed: July 24, 2020
    Publication date: January 28, 2021
    Inventors: Matthew KALO, Timothy Then-Chioh LU, Melicent Clare PECK, Siddharth SUKUMARAN, Yehong WANG, Chin Yat WONG, Peter William DAY
  • IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20200362003
    Abstract: The invention relates to IL-22 Fc fusion proteins, composition comprising the same, methods of making and/or purifying the same, methods of selecting batches of IL-22 Fc fusion proteins or compositions thereof, and methods of using the composition for the treatment of diseases (e.g., IBD).
    Type: Application
    Filed: July 24, 2020
    Publication date: November 19, 2020
    Inventors: Matthew KALO, Abigail Friederike Joyce PYNN, Lindsey Marie SILVA, Anjali SRIVASTAVA, Jayashree SUBRAMANIAN, Siddharth SUKUMARAN, Amy YOUNG, Tomasz BAGINSKI, Tracy Jane BENTLEY, Jeremy BESMER, Sherrie Patrice CURTIS, Peter William DAY
  • METHODS OF TREATING CANCER USING ANTI-OX40 ANTIBODIES AND PD-1 AXIS BINDING ANTAGONISTS
    Publication number: 20180256711
    Abstract: The invention provides methods of treating or delaying progression of cancer in an individual comprising administering to the individual an anti-human OX40 agonist antibody and an anti-PDL1 antibody. In some embodiments, the anti-human OX40 agonist antibody is administered in a dose selected from about 0.8 mg, about 3.2 mg, about 12 mg, about 40 mg, about 80 mg, about 130 mg, about 160 mg, about 300 mg, about 320 mg, about 400 mg, about 600 mg, and about 1200 mg, and the anti-PDL1 antibody is administered at a dose of about 800 mg or about 1200 mg.
    Type: Application
    Filed: December 14, 2017
    Publication date: September 13, 2018
    Applicant: Genentech, Inc.
    Inventors: Ina P. RHEE, Jeong KIM, Mahrukh HUSENI, Eric STEFANICH, Siddharth SUKUMARAN, Chi-Chung LI